The New solariX FTMS Based MALDI System is a Uniquely Powerful
Platform for Addressing Molecular Imaging of Small Molecules in Tissue
Samples.
SALT LAKE CITY, May 23, 2010 (BUSINESS WIRE) --At the 58th ASMS Conference on Mass Spectrometry and Allied Topics,
Bruker today announces a novel MALDI molecular imaging system based on
the extreme performance of the solariX
FTMS. The new MALDI-solariX combines the extreme
analytical performance of the solariX FTMS (resolving
power > 1,000,000 at m/z 400 at 7.0 tesla field strength) with a robust
and highly sensitive MALDI source to provide an unrivalled platform for
high performance molecular imaging of small molecules (e.g. drug,
metabolites, lipids) in tissue.
The new solariX MALDI source is based on a dual ion funnel
design that includes the combination of MALDI and ESI. This
unique source is capable of immediate and effortless switching between
the two ionization methods. The combination of MALDI with the solariX
FTMS addresses a need in the pharmaceutical industry and in academic
research institutions for a high performance imaging solution targeted
specifically to the tissue distribution of small molecule drugs and
metabolites, endogenous metabolic spatial profiling, and lipid imaging.
The solariX MALDI system incorporates the innovative,
proprietary smartbeamTMII
laser which includes a robust solid state 1 kHz laser with advanced
optics for molecular imaging, for:
-
Ultra-high mass resolution high-sensitivity small molecule MALDI-MS
imaging, without a loss in sensitivity due to MS/MS for selectivity
-
Sensitivity necessary to detect drugs and metabolites at therapeutic
dosages
-
Fast data acquisition of up to 1 pixel/sec with 1 kHz laser speed
-
Laser spot sizes down to 20 um allowing high spatial resolution
-
Instantaneous source switching allowing trouble free changeover from
ESI to MALDI
-
Highly effective workflow including MALDI imaging sample preparation
with the Bruker ImagePrep(TM)
station and data acquisition / image processing with FlexImaging(TM)
software
-
First commercially available software solution for small molecule
statistical class imaging utilizing ClinProTools(TM)
By combining molecular imaging with FTMS detection, researchers can
utilize ultra-high mass resolving power to separate and analyze
molecules of closely related masses in a truly multiplexed approach -
observing all molecular species simultaneously. This provides
selectivity without compromising sensitivity. Additionally,
industry-leading high mass accuracy (< 1 ppm) provides the requisite
specificity for elucidating molecular species without the need for time
consuming MS/MS. Complete, simultaneous, label-free mapping of drugs and
metabolites in tissue can now be conveyed from single MALDI imaging runs
at therapeutic dosing levels. For complete confidence in molecular
assignment of detected masses, Bruker's SmartFormula(TM)
software can be used as part of the small molecule imaging workflow for
assigning unambiguous elemental formula to detected peaks.
David Wagner, Section Manager of the DMPK group for GlaxoSmithKline,
remarked: "We are very excited to be adding this state-of-the-art
capability to the analytical analysis portfolio of our group. This
instrument will serve as the primary high-performance molecular imaging
solution for GSK's development efforts, and will provide unprecedented
power for the spatial analysis of target metabolites."
Full automation allows researchers to acquire data in a completely
unattended fashion and the unprecedented ease-of-use offered by the solariX
FTMS means MALDI data acquisition and imaging workflows require minimal
operator effort.
The solariX(TM) FTMS Based MALDI System will be
highlighted at Bruker's Users Meeting on Sunday, May 23rd, 2010 before
the 58th ASMS Conference on Mass Spectrometry in Salt Lake
City, Utah (USA). For more information on Bruker's User Meeting and
other ASMS activities, please visit www.bdal.com/asms2010.
For More Information:
For more information on the solariX(TM) FTMS Based MALDI
System please visit www.bdal.com/solarix
For information about Bruker Daltonics and Bruker Corporation (NASDAQ:
BRKR), please visit www.bruker.com
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6301724&lang=en
SOURCE: Bruker Daltonics
Bruker Daltonics
Darwin Asa, Ph.D., +1 (978) 663-3660, ext. 1149
Marketing Manager
dja@bdal.com